- $16.90bn
- $16.91bn
- $5.84m
Annual income statement for Vsee Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 6.8 | 7.34 | 6.38 | 5.84 |
| Cost of Revenue | ||||
| Gross Profit | 5.46 | 5.92 | 4.84 | 3.91 |
| Selling / General / Administrative Expenses | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 6.4 | 7.09 | 8.06 | 7.29 |
| Operating Profit | 0.405 | 0.252 | -1.68 | -1.45 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 0.359 | 0.386 | -1.62 | -1.57 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 0.259 | 0.278 | -0.926 | -3.41 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | 0.259 | 0.278 | -0.836 | -3.45 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 0.259 | 0.278 | -0.836 | -3.45 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.018 | 0.019 | -0.047 | -0.236 |